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Purpose or Objective: The dose coverage in patients 
diagnosed with high risk prostate adenocarcinoma with 
seminal vesicles affection don´t suppose any problem in dose 
escalation with HDR Brachytherapy. But we wonder if the 
quality prostate implant indicators will show any differences 
between standard patients (15-Gy HDR) and those with 
seminal vesicles affection(9-Gy HDR). To evaluate it, a 
multivariate analysis has been performed in our Radiation 
Oncology Department 
 
Material and Methods: 120 patients with high risk prostate 
adenocarcinoma were selected for the study and divided into 
two groups. The treatment schedule was external beam 
radiotherapy plus high dose rate brachytherapy as a boost:  
- Group A: 9-Gy boost - T3b high grade (seminal vesicles 
affection) 46-Gy to pelvic areas, up to 60-Gy in prostate and 
seminal vesicles (2-Gy per fraction) daily and 9-Gy HDR to 
prostatic gland and 1-2cm. of proximal seminal vesicles.  
- Group B: 15-Gy boost – High grade (no seminal vesicles 
affection)46-Gy to pelvic areas (2-Gy per fraction) daily 
treatment and 15-Gy HDR to prostatic gland.  
Volumetric Modulated Arc Therapy (VMAT) was the selected 
technique for external radiotherapy delivered in a Varian 
DHX Clinac (Varian, Palo Alto, Ca.) with Millennium 120-MLC. 
Brachytherapy was performed with VariSource iX afterloader 
(Varian, Palo Alto, Ca.). The aim is to demonstrate whether 
there are any differences in both groups for dose 
homogeneity index (DHI) and homogeneity index (HI). A 
multivariate analysis was developed using as variables three 
of prostate (PTV volume, D90 , D100), two of urethra (Dmax, 
D10) and two of rectum (Dmax , D10). 
 
Results: The multivariate analysis for both groups shows a p-
value of 0.452 to obtain the probability for DHI > 0,75 and a 
p-value of 0.897 to obtain a probability for HI>0.70. In Figure 
1, the plots of the results are presented: 
 
 
 
Conclusion: According to dose homogeneity, the analysis 
states that there were no significant differences for both 
studied groups. These results suggest the possibility of 
increasing the boost dose in T3b patients 
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Purpose or Objective: To validate the feasibility of a single-
fraction High Dose Rate Brachytherapy (HDRBT) Boost for 
prostate cancer using real-time Transrectal Ultrasound 
(TRUS) based planning. 
 
Material and Methods: From August 2012 to September 2015, 
113 patients underwent a single-fraction HDRBT boost of 15 
Gy using real-time TRUS based planning. External beam 
radiation therapy (EBRT) (37.5 Gy/15f or 44Gy/22f or 
45Gy/25f) was performed before (30%) or after (70%) HDRBT 
boost. We analyzed prostate, urethra and rectum dosimetrics 
data. Genito-Urinary (GU) and Gastro-Intestinal (GI) toxicity 
were assessed 4 and 12 months after the end of combined 
treatment using the International Prostate Symptom Score 
Scale (IPSS) and the Common Terminology Criteria for 
Adverse Events (CTCAE) v3.0.  
 
Results: Prostate D90 between 105% and 115% was achieved 
for 99% of patients, prostate V150 ≤ 40% for 99%, prostate 
V200 < 11% for 96%, urethra D10 <120% for 99%, urethra 
V125=0% for 100% and rectum V75<1cc for 95% of patients. 
Median IPSS score was 4 at the baseline and didn’t change at 
4 and 12 months after combined treatment. No patients 
developed ≥ grade 2 GI toxicity. With a median follow-up of 
10 months, only two patients experienced biochemical 
failure. Cumulative percentage of patients with PSA ≤ 1 at 4 
and 18 months was respectively 47% and 74 %. 
 
Conclusion: Single-fraction HDRBT boost of 15 Gy using real-
time TRUS based planning in combination with EBRT is a safe 
treatment with promising results. A longer follow-up is 
needed to assess long-term outcome and toxicities 
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Purpose or Objective: The aim of this study was to evaluate 
the acute and late toxicities and disease-specific and overall 
survival after interstitial brachytherapy for the treatment of 
gynecological and digestive tumors.  
 
Material and Methods: A retrospective study was carried out 
on a series of 19 patients referred for interstitial 
brachytherapy in our center between 2008 and 2013 with 
histologically proved locally advanced or recurrent 
gynecological malignancies and digestive tumors. Patients 
with distant metastases were excluded. Treatment consisted 
of brachytherapy alone (5p) (gynecological recurrence and 
anal carcinoma), or after surgery (1p) (rectal carcinoma) or 
after surgery and radiochemotherapy (4p) or after 
radiochemotherapy (9p). The radiochemotherapy with 
cisplatin-based chemotherapy regimens. Previously, 
recurrent patients (4p) were been treated with radiotherapy 
with or without concurrent chemotherapy. Medium dose of 
external beam radiotherapy was 51,7 Gy (range 45-70 Gy) 
followed by interstitial brachytherapy median implant dose 
22,3 Gy (range 9-38,5Gy). Inclusion criteria were as follows: 
Hb minimum 10gm/dl and performance status 70% or more. 
 
Results: Median age was 59 years (range 36-82). With a 
median follow-up of 14 months, local control was achieved 
on clinical examination or magnetic resonance imaging 93,8% 
patients. Among 19 patients studied, 3 lost follow-up and 
they were excluded from late toxicities and survival analysis. 
Eleven of the 19 patients (57,9%) experienced Radiation 
Therapy Oncology Group (RTOG) grade I or II acute toxicities 
proctitis (36,3%), cystitis (81,8%) and ephitelitis (18,2%). Not 
acute toxicities grades 3 or 4 were reported. Two of the 16 
patients (12,5%) experienced RTOG grade I or II late toxicities 
proctitis (6,25%) and cystitis (6,25%). Two of the 16 patients 
(12,5%) experienced RTOG grade III or IV late toxicities rectal 
ulcer (6,25%) and vulvar necrosis (6,25%). Using Kaplan-Meier 
analysis overall survival after minimum follow-up of 14 
months was 93% and disease-free survival was 75% (persistent 
tumor were included in this group). One patient had a 
locoregional recurrence and died of tumor. 
 
Conclusion: Interstitial brachytherapy is a good choice to 
deliver high-dose radiation in gynecological tumor after 
external beam radiotherapy or as an exclusive treatment in 
